Showing results (911-920 of 1,892) with videos related to
Sort By:
Pageof 190
Immunotherapy|October 1, 2026
Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancerCalogera Claudia Spagnolo, Irene Campo, Elena Fassi, et al.Immunotherapy|October 5, 2026
Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinomaZhiwei Zheng, Lisheng Huang, Yuling Zhang, et al.Immunotherapy|November 16, 2021
Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeuticConstanza Savid-Frontera, Maria E Viano, Natalia S Baez, et al.Immunotherapy|November 15, 2021
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summaryThomas Bieber, Eric L Simpson, Jonathan I Silverberg, et al.Immunotherapy|November 8, 2021
A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysisVictor Hémar, Etienne Rivière, Carine Greib, et al.Immunotherapy|November 30, 2021
Efficacy of mite allergen immunotherapy in allergic rhinitis and the immune synergistic effect on cross-allergensPeiyan Zheng, Xiaoqing Liu, Lili Lin, et al.Immunotherapy|February 22, 2019
Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature reviewSeren Durer, Ceren Durer, Madeeha Shafqat, et al.Immunotherapy|April 5, 2019
PD-L1 expressing granulomatous reaction as an on-target mechanism of steroid-refractory immune hepatotoxicityJames Rm Black, Robert D Goldin, Matthew Foxton, et al.Immunotherapy|September 19, 2019
Ixekizumab for treating ankylosing spondylitisSonam Kiwalkar, Secia Beier, Atul DeodharImmunotherapy|January 25, 2021
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?Stijn J De Keukeleire, Tijl Vermassen, Zahra M Nezhad, et al.Pageof 190